불면증 시장 : 전략적 인사이트와 예측(2026-2035년)

The global insomnia market is anticipated to grow at a CAGR of 14.6% from USD 3.59 billion in 2026 to USD 12.24 billion in 2035.

Healthcare providers are increasingly shifting from short-term symptom management toward comprehensive disease management, creating significant opportunities for innovative therapies and precision sleep medicine.

Insomnia is one of the most prevalent sleep disorders worldwide, affecting millions of individuals and significantly impairing physical health, mental well-being, cognitive performance, workplace productivity, and overall quality of life. The market continues to evolve as pharmaceutical companies develop novel therapies with improved efficacy, safety, and tolerability while healthcare systems strengthen screening, diagnosis, and long-term management programs. Advances in sleep neuroscience, orexin biology, digital health technologies, and personalized medicine are reshaping the treatment landscape and expanding commercial opportunities across global markets.

Market Drivers

Increasing Recognition of Insomnia as a Chronic Disease

Healthcare professionals increasingly recognize insomnia as a chronic medical condition rather than a temporary sleep complaint. This shift is driving earlier diagnosis, greater treatment initiation, and higher long-term demand for effective therapies.

Expansion of Orexin-Based Therapies

Growing clinical evidence supporting orexin receptor antagonists is transforming insomnia management. These targeted therapies offer improved efficacy with reduced risks of dependence and next-day sedation compared with conventional hypnotics, encouraging greater physician adoption.

Aging Global Population

The rising elderly population continues to increase the prevalence of chronic sleep disorders, creating sustained demand for effective and safe insomnia therapies suitable for long-term use.

Persistent Underdiagnosis

A substantial proportion of individuals with chronic insomnia remain undiagnosed or untreated. Improving public awareness, physician education, and sleep health initiatives continue to expand the addressable patient population.

Market Restraints

Concerns Regarding Long-Term Medication Use

Long-term pharmacological treatment remains associated with concerns related to dependence, tolerance, cognitive impairment, and residual daytime sedation, creating challenges for both clinicians and patients.

Limited Access to Sleep Specialists

Many healthcare systems continue to face shortages of sleep medicine specialists and dedicated sleep clinics, delaying diagnosis and treatment initiation.

Reimbursement and Cost Challenges

Healthcare payers increasingly require strong evidence of long-term clinical benefit and cost-effectiveness before approving reimbursement for premium-priced innovative therapies.

Market and Technology Insights

The global insomnia market can be segmented by development phase, mechanism of action, modality, and geography.

By development phase, the market includes preclinical pipeline, Phase I pipeline, Phase II pipeline, Phase III pipeline, and filed and under review assets. Continued investment across all development stages reflects growing confidence in the long-term commercial potential of insomnia therapeutics.

By mechanism of action, the market comprises orexin-based therapies, GABAergic therapies, circadian rhythm therapies, melatonin-based therapies, and novel mechanism-based therapies. Orexin-targeted therapies continue to gain momentum because of their differentiated mechanism and favorable safety profile.

By modality, the market includes small molecules, biologics, RNA therapies, cell therapies, and gene therapies. Small molecules currently dominate the market, while advanced therapeutic platforms represent emerging areas of research and innovation.

Technological advances including artificial intelligence-assisted drug discovery, wearable sleep monitoring devices, digital biomarkers, telemedicine, decentralized clinical trials, and real-world evidence are improving diagnosis, patient monitoring, clinical development, and treatment personalization.

Market Trends

The insomnia market continues to shift toward mechanism-driven and patient-centered treatment approaches.

Key market trends include:

• Rapid expansion of orexin receptor antagonist therapies.
• Growing investment in precision sleep medicine.
• Increasing use of artificial intelligence in drug discovery.
• Wider adoption of wearable sleep monitoring technologies.
• Greater integration of digital health and telemedicine.
• Expansion of patient awareness and screening programs.
• Increasing emphasis on long-term disease management rather than short-term symptom relief.

Regional Insights

North America continues to lead the global insomnia market owing to high disease awareness, strong healthcare infrastructure, widespread treatment accessibility, and significant pharmaceutical innovation. The United States remains the largest contributor because of advanced sleep medicine services and high adoption of innovative therapies.

Europe maintains a substantial market share through well-established healthcare systems, structured reimbursement pathways, and increasing recognition of the health burden associated with chronic insomnia.

Asia-Pacific is expected to witness the fastest growth during the forecast period due to improving healthcare infrastructure, rising disease awareness, expanding access to sleep medicine, and increasing pharmaceutical investment across China, Japan, South Korea, India, and Australia.

The Rest of the World is gradually expanding as healthcare modernization, public awareness campaigns, and improved access to diagnostic and treatment services strengthen sleep disorder management.

Competitive Landscape

The global insomnia market includes multinational pharmaceutical companies, biotechnology firms, specialty neuroscience companies, academic research institutions, and digital health innovators.

Market participants continue investing in orexin biology, precision medicine, artificial intelligence-enabled drug discovery, wearable sleep technologies, and next-generation therapeutic platforms. Strategic collaborations, licensing agreements, mergers and acquisitions, commercialization partnerships, and geographic expansion remain key competitive strategies.

Future Outlook

The future of the insomnia market will be driven by continued improvements in disease recognition, therapeutic innovation, and personalized medicine. Increasing understanding of sleep biology, expanding clinical evidence supporting orexin-targeted therapies, and broader integration of digital health technologies are expected to improve patient outcomes while expanding commercial opportunities.

Growing investment in precision medicine, biomarker development, wearable monitoring, and artificial intelligence is expected to accelerate innovation and support the development of safer, more effective long-term insomnia treatments.

Conclusion

The global Insomnia Market is expected to experience robust growth through 2035, supported by increasing disease awareness, expanding adoption of innovative orexin-based therapies, rising prevalence of chronic insomnia, and continued advances in sleep medicine. Although challenges related to long-term medication safety, reimbursement, and healthcare accessibility remain, ongoing innovation in targeted therapies, digital health, and precision medicine is expected to transform insomnia management and create significant opportunities for pharmaceutical companies, biotechnology firms, healthcare providers, and investors.

Key Benefits of this Report

• Comprehensive analysis of the global insomnia market and future growth opportunities.
• Detailed evaluation of market drivers, restraints, therapeutic innovations, and technology trends.
• Competitive assessment of leading companies, strategic developments, and commercialization activities.
• Insights into regional market dynamics, regulatory developments, and future investment opportunities.
• Valuable resource for pharmaceutical companies, biotechnology firms, healthcare providers, investors, researchers, consultants, and policymakers.

What Businesses Use Our Reports For

Market forecasting, competitive intelligence, investment analysis, product portfolio planning, licensing and partnership evaluation, commercialization strategy, regulatory planning, market entry assessment, and identification of emerging business opportunities.

Report Coverage

• Historical data from 2021 to 2024, Base Year 2025, and Forecast Period 2026 to 2035
• Comprehensive analysis of the global insomnia market by development phase, mechanism of action, modality, and geography
• Evaluation of market size, growth drivers, restraints, competitive landscape, and emerging therapeutic trends
• Assessment of company profiles, strategic collaborations, licensing activities, mergers and acquisitions, and commercialization strategies
• Analysis of orexin-based therapies, precision medicine, digital health technologies, artificial intelligence, and future market opportunities through 2035.

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Forecast Overview
  • 1.1.1 Global Insomnia Market Snapshot
  • 1.1.2 Forecast Assumptions and Scope
  • 1.1.3 Key Market Growth Drivers
  • 1.1.4 Major Market Constraints
  • 1.1.5 Strategic Forecast Highlights
• 1.2 Pipeline and Commercial Outlook
  • 1.2.1 Emerging Therapy Impact on Market Growth
  • 1.2.2 Pipeline-Driven Revenue Opportunities
  • 1.2.3 Competitive Market Evolution
  • 1.2.4 Innovation and Adoption Trends
  • 1.2.5 Key Strategic Conclusions
• 1.3 Analyst Perspective
  • 1.3.1 Future Market Structure
  • 1.3.2 Emerging Treatment Paradigms
  • 1.3.3 Long-Term Opportunity Assessment

2. Pipeline Overview

• 2.1 Global Insomnia Pipeline Landscape
  • 2.1.1 Active Pipeline Asset Inventory
  • 2.1.2 Historical Evolution of Insomnia Drug Development
  • 2.1.3 Sponsor Participation Trends
  • 2.1.4 Pipeline Maturity Assessment
  • 2.1.5 Innovation Trends
• 2.2 Pipeline Composition Analysis
  • 2.2.1 Assets by Development Phase
  • 2.2.2 Assets by Mechanism of Action
  • 2.2.3 Assets by Modality
  • 2.2.4 Assets by Target Patient Population
  • 2.2.5 Assets by Geographic Origin
• 2.3 Historical Progression Trends
  • 2.3.1 Historical Clinical Advancement Rates
  • 2.3.2 Regulatory Approval Trends
  • 2.3.3 Clinical Attrition Trends
  • 2.3.4 Commercialization Trends
  • 2.3.5 Development Timeline Benchmarking

3. Disease and Unmet Need Analysis

• 3.1 Disease Overview
  • 3.1.1 Chronic Insomnia Disorder
  • 3.1.2 Acute Insomnia
  • 3.1.3 Comorbid Insomnia
  • 3.1.4 Treatment-Resistant Insomnia
  • 3.1.5 Special Population Insomnia
• 3.2 Epidemiology and Disease Burden
  • 3.2.1 Global Disease Burden Assessment
  • 3.2.2 Diagnosis Trends
  • 3.2.3 Treatment Utilization Trends
  • 3.2.4 Healthcare Resource Burden
  • 3.2.5 Economic and Productivity Impact
• 3.3 Unmet Need Assessment
  • 3.3.1 Limitations of Existing Therapies
  • 3.3.2 Long-Term Management Challenges
  • 3.3.3 Treatment Adherence Challenges
  • 3.3.4 Residual Daytime Impairment Burden
  • 3.3.5 Future Treatment Needs

4. Mechanism and Modality Landscape

• 4.1 Mechanism of Action Clustering
  • 4.1.1 Dual Orexin Receptor Antagonists (DORAs)
  • 4.1.2 Selective Orexin Receptor Antagonists
  • 4.1.3 GABA-A Receptor Modulators
  • 4.1.4 Melatonin Receptor Agonists
  • 4.1.5 Circadian Rhythm Modulators
  • 4.1.6 Histaminergic Targets
  • 4.1.7 Serotonergic Targets
  • 4.1.8 Novel Mechanistic Approaches
• 4.2 Innovation Benchmarking
  • 4.2.1 First-in-Class Asset Assessment
  • 4.2.2 Best-in-Class Potential Assessment
  • 4.2.3 Clinical Differentiation Analysis
  • 4.2.4 Commercial Differentiation Analysis
  • 4.2.5 Future Innovation Opportunities
• 4.3 Modality Analysis
  • 4.3.1 Small Molecules
  • 4.3.2 Biologics
  • 4.3.3 RNA Therapies
  • 4.3.4 Cell Therapies
  • 4.3.5 Gene Therapies

5. Clinical Development Intelligence

• 5.1 Clinical Trial Landscape
  • 5.1.1 Active Clinical Trial Inventory
  • 5.1.2 Historical Trial Activity Trends
  • 5.1.3 Recruitment Activity Analysis
  • 5.1.4 Trial Completion Trends
  • 5.1.5 Future Clinical Development Programs
• 5.2 Trial Design Benchmarking
  • 5.2.1 Sample Size Benchmarking
  • 5.2.2 Endpoint Benchmarking
  • 5.2.3 Trial Duration Benchmarking
  • 5.2.4 Comparator Analysis
  • 5.2.5 Patient Population Benchmarking
• 5.3 Clinical Success Intelligence
  • 5.3.1 Success Rates by Development Phase
  • 5.3.2 Success Rates by Mechanism
  • 5.3.3 Failure Trend Analysis
  • 5.3.4 Recruitment Challenges
  • 5.3.5 Dropout Trend Analysis

6. Pipeline Segmentation Analysis

• 6.1 Pipeline by Development Phase
  • 6.1.1 Preclinical Pipeline
    • 6.1.1.1 Asset Inventory and Count
    • 6.1.1.2 Developer Analysis
    • 6.1.1.3 Mechanism Distribution
    • 6.1.1.4 Commercial Potential Assessment
    • 6.1.1.5 Advancement Probability
  • 6.1.2 Phase I Pipeline
    • 6.1.2.1 Asset Inventory and Count
    • 6.1.2.2 Asset-Level Profiles
    • 6.1.2.3 Early Clinical Findings
    • 6.1.2.4 Competitive Positioning
    • 6.1.2.5 Advancement Probability
  • 6.1.3 Phase II Pipeline
    • 6.1.3.1 Asset Inventory and Count
    • 6.1.3.2 Asset-Level Profiles
    • 6.1.3.3 Proof-of-Concept Assessment
    • 6.1.3.4 Commercial Potential
    • 6.1.3.5 Advancement Probability
  • 6.1.4 Phase III Pipeline
    • 6.1.4.1 Asset Inventory and Count
    • 6.1.4.2 Asset-Level Profiles
    • 6.1.4.3 Registrational Strategy Assessment
    • 6.1.4.4 Market Readiness Evaluation
    • 6.1.4.5 Approval Probability
  • 6.1.5 Filed and Under Review Assets
    • 6.1.5.1 Asset Inventory and Count
    • 6.1.5.2 Regulatory Status
    • 6.1.5.3 Approval Timeline Assessment
    • 6.1.5.4 Launch Readiness Evaluation
• 6.2 Pipeline by Mechanism of Action
  • 6.2.1 Orexin-Based Therapies
  • 6.2.2 GABAergic Therapies
  • 6.2.3 Circadian Rhythm Therapies
  • 6.2.4 Melatonin-Based Therapies
  • 6.2.5 Novel Mechanism-Based Therapies
• 6.3 Pipeline by Modality
  • 6.3.1 Small Molecules
  • 6.3.2 Biologics
  • 6.3.3 RNA Therapies
  • 6.3.4 Cell Therapies
  • 6.3.5 Gene Therapies

7. Probability of Success and Risk Analysis

• 7.1 Phase Transition Probability Modeling
  • 7.1.1 Preclinical to Phase I
  • 7.1.2 Phase I to Phase II
  • 7.1.3 Phase II to Phase III
  • 7.1.4 Phase III to Approval
  • 7.1.5 Overall Approval Probability
• 7.2 Risk-Adjusted Pipeline Assessment
  • 7.2.1 Asset-Level Risk Scoring
  • 7.2.2 Mechanism-Based Risk Assessment
  • 7.2.3 Regulatory Risk Assessment
  • 7.2.4 Commercial Risk Assessment
  • 7.2.5 Competitive Risk Assessment
• 7.3 Attrition Analysis
  • 7.3.1 Historical Attrition Trends
  • 7.3.2 Attrition by Phase
  • 7.3.3 Attrition by Mechanism
  • 7.3.4 Sponsor-Based Attrition Trends
  • 7.3.5 Key Failure Drivers
• 7.4 Probability-Weighted Revenue Potential
  • 7.4.1 Risk-Adjusted Revenue Modeling
  • 7.4.2 Peak Sales Probability Assessment
  • 7.4.3 Scenario-Based Forecast Analysis
  • 7.4.4 Sensitivity Analysis

8. Launch Timeline and Commercial Potential

• 8.1 Approval Timeline Forecasting
  • 8.1.1 Regulatory Submission Forecasts
  • 8.1.2 Approval Timeline Forecasts
  • 8.1.3 Launch Sequencing Analysis
  • 8.1.4 Competitive Entry Timing
• 8.2 Commercial Forecasting
  • 8.2.1 Market Expansion Drivers
  • 8.2.2 Adoption Curve Forecasting
  • 8.2.3 Treatment Switching Dynamics
  • 8.2.4 Market Penetration Forecasts
• 8.3 Revenue Opportunity Assessment
  • 8.3.1 Asset-Level Commercial Potential
  • 8.3.2 Mechanism-Level Opportunity Analysis
  • 8.3.3 Geographic Revenue Potential
  • 8.3.4 Peak Sales Potential

9. Competitive Pipeline Landscape

• 9.1 Company-Wise Pipeline Strength Assessment
  • 9.1.1 Leading Developers
  • 9.1.2 Challenger Companies
  • 9.1.3 Emerging Biotech Innovators
  • 9.1.4 Academic and Research Sponsors
• 9.2 Competitive Benchmarking
  • 9.2.1 Pipeline Breadth Assessment
  • 9.2.2 Pipeline Depth Assessment
  • 9.2.3 Innovation Leadership Analysis
  • 9.2.4 Commercial Positioning Analysis
• 9.3 Asset Concentration Analysis
  • 9.3.1 Top Assets by Commercial Potential
  • 9.3.2 Top Assets by Innovation Potential
  • 9.3.3 High-Risk High-Reward Assets
  • 9.3.4 White Space Opportunities

10. Geographic Analysis

• 10.1 North America
  • 10.1.1 Clinical Trial Activity
  • 10.1.2 Regulatory Environment
  • 10.1.3 Innovation Hubs
  • 10.1.4 Commercial Opportunity Assessment
• 10.2 Europe
  • 10.2.1 Clinical Trial Activity
  • 10.2.2 Regulatory Environment
  • 10.2.3 Innovation Hubs
  • 10.2.4 Commercial Opportunity Assessment
• 10.3 Asia-Pacific
  • 10.3.1 Clinical Trial Activity
  • 10.3.2 Regulatory Environment
  • 10.3.3 Innovation Hubs
  • 10.3.4 Commercial Opportunity Assessment
• 10.4 Latin America
  • 10.4.1 Clinical Trial Activity
  • 10.4.2 Regulatory Environment
  • 10.4.3 Innovation Hubs
  • 10.4.4 Commercial Opportunity Assessment
• 10.5 Middle East and Africa
  • 10.5.1 Clinical Trial Activity
  • 10.5.2 Regulatory Environment
  • 10.5.3 Innovation Hubs
  • 10.5.4 Commercial Opportunity Assessment

11. Key Countries Analysis

• 11.1 United States
  • 11.1.1 Trial Activity Assessment
  • 11.1.2 Regulatory Timeline Analysis
  • 11.1.3 Key Sponsors
  • 11.1.4 Commercial Opportunity Assessment
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 China
• 11.9 Japan
• 11.10 India
• 11.11 South Korea
• 11.12 Australia
• 11.13 Brazil
• 11.14 Mexico
• 11.15 Saudi Arabia
• 11.16 South Africa

12. Deals and Investment Landscape

• 12.1 Licensing Activity
  • 12.1.1 Asset Licensing Trends
  • 12.1.2 Regional Licensing Activity
  • 12.1.3 Mechanism-Specific Licensing Trends
• 12.2 Strategic Collaborations
  • 12.2.1 Co-Development Agreements
  • 12.2.2 Research Collaborations
  • 12.2.3 Commercialization Partnerships
• 12.3 Mergers and Acquisitions
  • 12.3.1 Pipeline Asset Acquisitions
  • 12.3.2 Strategic Consolidation Trends
  • 12.3.3 Portfolio Expansion Transactions
• 12.4 Funding Trends
  • 12.4.1 Venture Capital Activity
  • 12.4.2 Private Equity Activity
  • 12.4.3 Public Market Financing
  • 12.4.4 Funding by Development Stage

13. Future Outlook and Strategic Insights

• 13.1 Future Market Evolution
  • 13.1.1 Orexin Market Expansion Outlook
  • 13.1.2 Emerging Therapy Impact
  • 13.1.3 Future Standard-of-Care Evolution
  • 13.1.4 Precision Medicine Opportunities
• 13.2 Strategic Opportunity Assessment
  • 13.2.1 High-Growth Market Opportunities
  • 13.2.2 Geographic Expansion Opportunities
  • 13.2.3 Partnership Opportunities
  • 13.2.4 White Space Opportunities
• 13.3 Long-Term Commercial Outlook
  • 13.3.1 Future Market Leaders
  • 13.3.2 Competitive Dynamics
  • 13.3.3 Long-Term Revenue Outlook

14. Methodology and Data Framework

• 14.1 Research Methodology
  • 14.1.1 Pipeline Identification Framework
  • 14.1.2 Market Forecasting Methodology
  • 14.1.3 Revenue Modeling Framework
  • 14.1.4 Asset Validation Protocol
• 14.2 Data Sources
  • 14.2.1 ClinicalTrials.gov
  • 14.2.2 EU Clinical Trials Register
  • 14.2.3 Regulatory Filings
  • 14.2.4 Company Pipeline Disclosures
  • 14.2.5 Government Healthcare Databases
  • 14.2.6 Peer-Reviewed Publications
• 14.3 Forecasting and Modeling Methodology
  • 14.3.1 Probability of Success Modeling
  • 14.3.2 Risk Adjustment Framework
  • 14.3.3 Revenue Forecast Methodology
  • 14.3.4 Commercial Opportunity Modeling
• 14.4 Validation and Limitations
  • 14.4.1 Data Quality Assessment
  • 14.4.2 Assumptions Framework
  • 14.4.3 Model Limitations
  • 14.4.4 Verification Protocol